Vertex seeks to mobilise Sh5 billion for the Bond Fund through the issuance of 50 million units, and a further Sh5 billion ...

Vertex is severing one of its ties to CRISPR Therapeutics. The big biotech has chosen to opt out of the diabetes gene-edited stem cell therapy it gained through the acquisition of ViaCyte, leaving ...

Pharma Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia By Kevin Dunleavy Jan 16, 2024 3:40pm CRISPR Vertex Pharmaceuticals FDA Casgevy (exa-cel) ...

Vertex said all 12 achieved levels of blood glucose in the range recommended by the American Diabetes Association (ADA). Type 1 diabetes treatment requires blood glucose monitoring and frequent or ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes – Vertex to initiate a Phase 1/2 ...

Now, Vertex has joined Skyhawk’s roster of A-list partners. Vertex is paying $40 million for options to license small molecules against targets covered by the collaboration. The nature of the ...